ATE535284T1 - Zusammensetzungen die non-typable haemophilus influenzae (nthi) und probiotische bakterien enthalten zur behandlung von nthi verursachten schleimhautinfektionen - Google Patents
Zusammensetzungen die non-typable haemophilus influenzae (nthi) und probiotische bakterien enthalten zur behandlung von nthi verursachten schleimhautinfektionenInfo
- Publication number
- ATE535284T1 ATE535284T1 AT01931225T AT01931225T ATE535284T1 AT E535284 T1 ATE535284 T1 AT E535284T1 AT 01931225 T AT01931225 T AT 01931225T AT 01931225 T AT01931225 T AT 01931225T AT E535284 T1 ATE535284 T1 AT E535284T1
- Authority
- AT
- Austria
- Prior art keywords
- nthi
- treatment
- compositions containing
- containing non
- haemophilus influenzae
- Prior art date
Links
- 208000015181 infectious disease Diseases 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 241000894006 Bacteria Species 0.000 title 1
- 241000606768 Haemophilus influenzae Species 0.000 title 1
- 229940047650 haemophilus influenzae Drugs 0.000 title 1
- 239000006041 probiotic Substances 0.000 title 1
- 230000000529 probiotic effect Effects 0.000 title 1
- 235000018291 probiotics Nutrition 0.000 title 1
- 206010065764 Mucosal infection Diseases 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 229940126578 oral vaccine Drugs 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 210000002345 respiratory system Anatomy 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPQ7612A AUPQ761200A0 (en) | 2000-05-19 | 2000-05-19 | Compositions and methods for treatment of mucosal infections |
PCT/AU2001/000588 WO2001087332A1 (en) | 2000-05-19 | 2001-05-21 | Compositions and methods for treatment of mucosal infections |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE535284T1 true ATE535284T1 (de) | 2011-12-15 |
Family
ID=3821690
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01931225T ATE535284T1 (de) | 2000-05-19 | 2001-05-21 | Zusammensetzungen die non-typable haemophilus influenzae (nthi) und probiotische bakterien enthalten zur behandlung von nthi verursachten schleimhautinfektionen |
Country Status (10)
Country | Link |
---|---|
US (1) | US8637051B2 (de) |
EP (1) | EP1305042B1 (de) |
JP (2) | JP5567756B2 (de) |
KR (1) | KR20030019389A (de) |
CN (1) | CN1437480A (de) |
AT (1) | ATE535284T1 (de) |
AU (1) | AUPQ761200A0 (de) |
BR (1) | BR0110971A (de) |
CA (1) | CA2409813C (de) |
WO (1) | WO2001087332A1 (de) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPQ761200A0 (en) * | 2000-05-19 | 2000-06-15 | Hunter Immunology Limited | Compositions and methods for treatment of mucosal infections |
US7371721B2 (en) | 2000-09-18 | 2008-05-13 | Sanos Bioscience A/S | Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes |
TWI350174B (en) * | 2003-03-12 | 2011-10-11 | Wyeth Corp | Adjuvanted bovine vaccines |
WO2005077409A1 (en) * | 2004-02-18 | 2005-08-25 | The University Of Newcastle Research Associates Limited | A vaccine formulated for administration to mucosa of the lungs |
US7862808B2 (en) | 2004-07-01 | 2011-01-04 | Mead Johnson Nutrition Company | Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12 |
CN101060852A (zh) * | 2004-08-17 | 2007-10-24 | 亨特免疫有限公司 | 口服灭活疫苗及其提供方法 |
US20070269376A1 (en) * | 2004-08-17 | 2007-11-22 | Hunter Immunology Limited | Method for Determining Dosage for an Oral Killed Vaccine |
US7303745B2 (en) * | 2005-04-15 | 2007-12-04 | Bristol-Myers Squibb Company | Method for preventing or treating the development of respiratory allergies |
US20060233762A1 (en) * | 2005-04-15 | 2006-10-19 | Mcmahon Robert J | Method for treating or preventing systemic inflammation in formula-fed infants |
CN102905992B (zh) | 2010-03-18 | 2014-08-13 | 永备电池有限公司 | 钮扣电池分配封装件 |
US20130150286A1 (en) * | 2010-06-25 | 2013-06-13 | Jean-Claude Sirard | Methods and pharmaceutical compositions for the treatment of respiratory tract infections |
WO2013028756A1 (en) | 2011-08-22 | 2013-02-28 | Carnegie Mellon University | Atom transfer radical polymerization under biologically compatible conditions |
CN106456740B (zh) * | 2014-05-02 | 2021-06-08 | Qu生物制药公司 | 抗微生物免疫调节 |
US9982070B2 (en) | 2015-01-12 | 2018-05-29 | Carnegie Mellon University | Aqueous ATRP in the presence of an activator regenerator |
CN111529703B (zh) * | 2020-06-17 | 2023-09-15 | 湖南循天然营养有限公司 | 一种组合物及其制备方法与在制备免疫佐剂中的应用 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA907737B (en) * | 1989-09-29 | 1991-07-31 | Nisshin Oil Mills Ltd | Stable immunogen composition for oral administration |
US6231870B1 (en) * | 1995-06-02 | 2001-05-15 | Uab Research Foundation | Oral administration of pneumoccal antigens |
JPH0680575A (ja) * | 1991-03-05 | 1994-03-22 | Meiji Milk Prod Co Ltd | 経口免疫賦活剤 |
WO1997045139A2 (en) | 1996-05-31 | 1997-12-04 | Genetics Institute, Inc. | Il-12 as an adjuvant for bordetella pertussis vaccines |
WO1998056415A1 (en) | 1997-06-11 | 1998-12-17 | Aquila Biopharmaceuticals, Inc. | Purified saponins as oral adjuvants |
AU9310298A (en) * | 1997-09-09 | 1999-03-29 | Trustees Of Columbia University In The City Of New York, The | T-independent conjugate-vaccines |
US6153182A (en) | 1997-12-19 | 2000-11-28 | Uab Research Foundation | Lymphotactin as an adjuvant |
ID26327A (id) * | 1997-12-23 | 2000-12-14 | Genesis Res & Dev Corp Ltd | Komposisi-komposisi turunan dari mycobacterium vaccae dan metoda untuk penggunaannya |
GB9727262D0 (en) * | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
GB9801870D0 (en) * | 1998-01-28 | 1998-03-25 | Raby Limited | Vaccine composition |
CA2584482C (en) | 1998-02-05 | 2012-03-27 | Smithkline Beecham Biologicals S.A. | Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination |
SE9800615D0 (sv) * | 1998-02-27 | 1998-02-27 | Ingvar Sjoeholm | Mucosal microparticle conjugate vaccine |
CA2322337A1 (en) | 1998-03-05 | 1999-09-10 | The Medical College Of Ohio | Enhancement of immunity by intranasal inoculation of il-12 |
US5985264A (en) * | 1998-03-05 | 1999-11-16 | The Medical College Of Ohio | IL-12 Stimulation of Neonatal immunity |
FR2776521B1 (fr) * | 1998-03-27 | 2000-12-15 | Pf Medicament | Utilisation de conjugues p40 actifs par voie nasale |
AU4376199A (en) * | 1998-06-26 | 2000-01-17 | Pasteur Merieux Serums Et Vaccins | Mucosal targeting immunisation |
AR020102A1 (es) | 1998-07-30 | 2002-04-10 | Ucb Sa | Compuesto para la prevencion y/o tratamiento de la alergia; composicion farmaceutica, composicion cosmetica, composicion en forma de bebida, alimento y/oalimento para animales domesticos que lo comprende y uso de dicho compuesto o dicha composicion farmaceutica para la fabricacion de un alimento |
GB9909077D0 (en) * | 1999-04-20 | 1999-06-16 | Smithkline Beecham Biolog | Novel compositions |
US7223398B1 (en) * | 1999-11-15 | 2007-05-29 | Dynavax Technologies Corporation | Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof |
US20020044926A1 (en) * | 1999-12-10 | 2002-04-18 | Gregor Reid | Oral administration of lactobacillus for the treatment and prevention of urogenital infection |
AUPQ761200A0 (en) * | 2000-05-19 | 2000-06-15 | Hunter Immunology Limited | Compositions and methods for treatment of mucosal infections |
EP1303300B1 (de) * | 2000-06-19 | 2010-08-11 | Hunter Immunology Limited | Zusammensetzungen und methoden zur behandlung von candidosen |
EP1311684A4 (de) * | 2000-08-08 | 2005-10-19 | Genesis Res & Dev Corp Ltd | Lactobacillus rhamnosus polynukleotide, polypeptide und methoden zu deren verwendung |
-
2000
- 2000-05-19 AU AUPQ7612A patent/AUPQ761200A0/en not_active Abandoned
-
2001
- 2001-05-21 US US10/276,829 patent/US8637051B2/en not_active Expired - Fee Related
- 2001-05-21 CN CN01811367A patent/CN1437480A/zh active Pending
- 2001-05-21 KR KR1020027015631A patent/KR20030019389A/ko not_active Application Discontinuation
- 2001-05-21 JP JP2001583799A patent/JP5567756B2/ja not_active Expired - Fee Related
- 2001-05-21 CA CA2409813A patent/CA2409813C/en not_active Expired - Lifetime
- 2001-05-21 EP EP01931225A patent/EP1305042B1/de not_active Expired - Lifetime
- 2001-05-21 BR BR0110971-5A patent/BR0110971A/pt not_active Application Discontinuation
- 2001-05-21 WO PCT/AU2001/000588 patent/WO2001087332A1/en active IP Right Grant
- 2001-05-21 AT AT01931225T patent/ATE535284T1/de active
-
2012
- 2012-03-30 JP JP2012080832A patent/JP2012153706A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN1437480A (zh) | 2003-08-20 |
JP5567756B2 (ja) | 2014-08-06 |
WO2001087332A1 (en) | 2001-11-22 |
EP1305042A1 (de) | 2003-05-02 |
BR0110971A (pt) | 2005-04-05 |
EP1305042B1 (de) | 2011-11-30 |
JP2012153706A (ja) | 2012-08-16 |
CA2409813C (en) | 2013-11-12 |
KR20030019389A (ko) | 2003-03-06 |
EP1305042A4 (de) | 2005-02-02 |
US20040057965A1 (en) | 2004-03-25 |
JP2003533489A (ja) | 2003-11-11 |
CA2409813A1 (en) | 2001-11-22 |
AUPQ761200A0 (en) | 2000-06-15 |
US8637051B2 (en) | 2014-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE535284T1 (de) | Zusammensetzungen die non-typable haemophilus influenzae (nthi) und probiotische bakterien enthalten zur behandlung von nthi verursachten schleimhautinfektionen | |
ATE475423T1 (de) | Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen | |
DE60119734D1 (de) | Hpv-e7 zur behandlung von menschlichem papillomavirus | |
ATE493433T1 (de) | Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen | |
ATE439138T1 (de) | Probiotika zur primären prävention atopischer erkrankungen | |
HUP0203056A1 (hu) | Vakcinakészítmény | |
ATE522623T1 (de) | Zusammensetzungen und verfahren zur behandlung und diagnose von lungentumoren | |
BR0015698A (pt) | Composições e métodos para tratamento de doenças alérgicas | |
ATE430154T1 (de) | Amino-substituierte cyclohexan derivate zur behandlung bakterieller infektionen | |
NO976119D0 (no) | OMP26-antigen fra Haemophilus influenzae | |
EP1362127A4 (de) | Serpin-arzneistoffe zur behandlung einer hiv-infektion und verfahren zu deren verwendung | |
ATE464045T1 (de) | Zusammensetzung aus milchsäure und lactoferrin | |
ATE291927T1 (de) | Peptide zur behandlung von beeinträchtigten zwischenmenschlischen störungen und verhaltenstörungen | |
DE60001687D1 (de) | Trovafloxacin enhaltende Suspensionen zur oralen Anwendung | |
DE69840027D1 (de) | Synthetische peptidkonstrukte zur erkennung und behandlung von parodontose hervorgerufen durch porphyromonas gingivalis | |
DE602004022689D1 (de) | Verwendung probiotischer bakterien zur behandlung von infektionen | |
DE602004028574D1 (de) | Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie | |
ATE355069T1 (de) | Verfahren zur herstellung polyvalenter bakteriophagenpräparationen zur behandlung bakterieller infektionen | |
DE60231475D1 (de) | Materialien und methoden zur behandlung von hepatitis c | |
DE60142786D1 (de) | Zusammensetzungen und methoden zur behandlung von candidosen | |
DE60130906D1 (de) | Die synergistischen wirkungen von hgf und antibakterieller behandlung | |
DE602005027228D1 (de) | Zusammensetzungen und verfahren zur behandlung von krankheiten, die durch infektion mit yersinia spp ausgelöst sind | |
ATE457730T1 (de) | Verabreichung von produkten des 5-lipoxygenase synthesewegs zur behandlung von mikrobiellen infektionen | |
DE60135232D1 (de) | Nukleinsäure und korrespondierendes protein 85p1b3, nützlich zur behandlung und detektion von krebserkrankungen | |
ATE313628T1 (de) | Klonierung und expression von haemophilus somnus transferrin-bindenden proteinen |